In particular, we have demonstrated that STAT6 and PDAP1, via a putative STAT6–ERK–NF-κB network, may represent useful molecular targets for treatment-resistant ALL, particularly in the absence of clinically available IGF1/R inhibitors. The gene discussed is PDAP1; the disease is acute lymphoblastic leukemia.